Dose- and Time-Dependent Neuroprotective Effects of Pycnogenol® following Traumatic Brain Injury

Mubeen A. Ansari  
*University of Kentucky*, mubeen.ansari@uky.edu

Kelly N. Roberts  
*University of Kentucky*, knrobe2@uky.edu

Stephen W. Scheff  
*University of Kentucky*, sscheff@email.uky.edu

Follow this and additional works at: [https://uknowledge.uky.edu/sbcoa_facpub](https://uknowledge.uky.edu/sbcoa_facpub)

Part of the [Family, Life Course, and Society Commons](https://uknowledge.uky.edu/familylife/), and the [Geriatrics Commons](https://uknowledge.uky.edu/geriatrics)

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Repository Citation
Ansari, Mubeen A.; Roberts, Kelly N.; and Scheff, Stephen W., "Dose- and Time-Dependent Neuroprotective Effects of Pycnogenol® following Traumatic Brain Injury" (2013). *Sanders-Brown Center on Aging Faculty Publications*. 28.  
[https://uknowledge.uky.edu/sbcoa_facpub/28](https://uknowledge.uky.edu/sbcoa_facpub/28)

This Article is brought to you for free and open access by the Aging at UKnowledge. It has been accepted for inclusion in Sanders-Brown Center on Aging Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Dose- and Time-Dependent Neuroprotective Effects of Pycnogenol® following Traumatic Brain Injury

Digital Object Identifier (DOI)
http://dx.doi.org/10.1089/neu.2013.2910

Notes/Citation Information
Published in Journal of Neurotrauma, v. 30, no. 17, p. 1542-1549.

This is a copy of an article published in the Journal of Neurotrauma (c) 2013, copyright Mary Ann Liebert, Inc.; Journal of Neurotrauma is available online at: http://online.liebertpub.com.

This article is available at UKnowledge: https://uknowledge.uky.edu/sbcoa_facpub/28
Dose- and Time-Dependent Neuroprotective Effects of Pycnogenol® following Traumatic Brain Injury

Mubeen A. Ansari, Kelly N. Roberts, and Stephen W. Scheff

Abstract

After traumatic brain injury (TBI), both primary and secondary injury cascades are initiated, leading to neuronal death and cognitive dysfunction. We have previously shown that the combinational bioflavonoid, Pycnogenol® (PYC), alters some secondary injury cascades and protects synaptic proteins when administered immediately following trauma. The purpose of the present study was to explore further the beneficial effects of PYC and to test whether it can be used in a more clinically relevant fashion. Young adult male Sprague-Dawley rats were subjected to a unilateral moderate/severe cortical contusion. Subjects received a single intravenous (i.v.) injection of PYC (1, 5, or 10 mg/kg) or vehicle, with treatment initiated at 15 min, 2 h, or 4 h post injury. All rats were killed at 96 h post TBI. Both the cortex and hippocampus ipsilateral and contralateral to the injury were evaluated for possible changes in oxidative stress (thiobarbituric acid reactive species; TBARS) and both pre- and post-synaptic proteins (synapsin-I, synaptophysin, drebrin, post synaptic density protein-95, and synapse associated protein-97). Following TBI, TBARS were significantly increased in both the injured cortex and ipsilateral hippocampus. Regardless of the dose and delay in treatment, PYC treatment significantly lowered TBARS. PYC treatment significantly protected both the cortex and hippocampus from injury-related declines in pre- and post-synaptic proteins. These results demonstrate that a single i.v. treatment of PYC is neuroprotective after TBI with a therapeutic window of at least 4 h post trauma. The natural bioflavonoid PYC may provide a possible therapeutic intervention in neurotrauma.

Key words: bioflavonoids; natural compounds; neurotrauma; oxidative stress; pycnogenol; synaptic proteins; traumatic brain injury

Introduction

It is estimated that approximately 1.7 million individuals in the United States will suffer traumatic brain injury (TBI) this year, with a large percentage requiring hospitalization. Multiple primary and secondary injury cascades are involved in TBI, which result in delayed neuronal dysfunction, synapse loss, and cell death. These secondary injury cascades can occur very rapidly, within minutes or hours after the trauma and last for days or weeks. Although there are many different factors, most researchers believe that pharmacologic intervention following trauma can disrupt these cascades and result in a more positive outcome. It is now clear that therapeutic intervention needs to be a multifaceted approach to target several components in a complimentary way. Such a pharmacologic therapeutic regime would have to take into consideration drug compatibility and timing issues.

As part of the secondary injury cascade, there are large transient increases in excitatory neurotransmitter efflux that result in excitotoxicity, ATP depletion, ionic imbalance, proteolysis, and oxidative stress. Due to its high content of polyunsaturated fatty acids, the brain is extremely sensitive to stress and particularly vulnerable to free radical attacks and lipid peroxidation. A close relationship exists between the degree of oxidative stress and the pathogenesis of TBI. Oxidative stress-related cascades resulting from TBI have been implicated in cytoskeletal damage, mitochondrial dysfunction, and altered signal transduction. Therapeutic intervention following TBI would have to disrupt the secondary injury cascades, such as oxidative stress, in order to promote a positive outcome.

Increased oxidative stress can affect the function and transportation of mitochondria to synapses, that might associate with the loss of synaptic function and neurodegeneration after brain injury. We have previously shown that following TBI there is a significant loss of synaptic proteins in both the cortex and hippocampus. This synaptic change occurs much later than the increase in levels of oxidative stress, which is a very early and long-lasting event. This early increase in oxidative stress and related cascades may play important role in synaptic loss following TBI and be responsible for behavioral dysfunction as a consequence of the injury. Therapeutic interventions must be able to afford protection of synaptic homeostasis.
Initiation of therapy immediately following the trauma would provide the greatest protection, provided that all cascades had the identical time course but this may not be the case. For a potential therapy to be clinically relevant, it must be able to alter secondary injury cascades when administered at extended times post trauma. In addition, since the injury cascades are complex, a rationale therapy would have to be able to alter multiple secondary injury cascades. A previous study from our laboratory showed neuroprotective effects of Pycnogenol® (PYC) in a rodent model of TBI. PYC is a patented combination of bioflavonoids extracted from the bark of French maritime pine tree (Pinus maritima) and has a high capacity to scavenge free radicals and promote cellular health. Bioflavonoids are natural compounds that are known as neuroprotective agents, due in part to their antioxidant and anti-inflammatory properties and their ability to modulate intracellular signaling. In our previous study, animals were treated with multiple high intraperitoneal doses of PYC immediately after the trauma. The neuroprotective effects of PYC shown in that study were not limited to only antioxidant and anti-inflammatory actions, but also spared synaptic proteins after neurotrauma, suggesting an agent that addresses multiple aspects of the pathophysiology following trauma. In the present series of studies, we investigated whether a single intravenous (i.v.) treatment of PYC given at delayed times post injury would also afford neuroprotection and alter levels of oxidative stress.

**Methods**

**Chemicals**

Mouse monoclonal anti β-actin, goat polyclonal anti PSD-95, and anti-synapse associated protein-97 (SAP-97) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal anti synapsin-I and anti synaptophysin were purchased from Millipore (Millipore Inc. MA, USA). Rabbit polyclonal anti-drebrin, alkaline phosphatase conjugated anti-mouse, anti-goat, anti-rabbit secondary antibodies, and all other chemicals and reagents used were purchased from Sigma (St Louis, MO, USA). Electrophoresis materials and chemicals were purchased from Bio-Rad (Hercules, CA, USA) unless stated otherwise. PYC was gifted from Horphag Research Inc. USA.

**Animals and surgical procedure**

Adult male Sprague-Dawley rats (n = 74, 250–275 g; Harlan Laboratories, Indianapolis, IN) were housed in group cages (2 per cage) on a 12 h light/dark cycle with free access to food and water. All experimental protocols and procedures involving animals were approved by the Animal Care and Use Committee of the University of Kentucky. The animals were randomly assigned to one of twelve groups: Vehicle or PYC (1 mg/kg, 5 mg/kg, 10 mg/kg) with i.v. treatment beginning at 15 min, 2 h, or 4 h post trauma. All injections were administered via the tail vein with the total volume of each injection 100 μL. For injections occurring at 2 h and 4 h post injury, animals were anesthetized with 2% isoflurane. Unilateral cortical contusions were carried out under isoflurane anesthesia (2%) as previously described. All injuries were completed using an electronic-controlled pneumatic impact device (TBI 0310, Precision Systems & Instrumentation, Fairfax Station, VA) with a hard stop Bimba cylinder (Bimba Manufacturing, Monee, IL) and a beveled 5-mm impactor tip. The depth of impact was 2.0 mm from the cortical surface with an impact velocity of 3.5 m/sec and a dwell time of 500 msec. The body temperature of each rat was monitored and maintained at 37°C. The animals were allowed to survive for 96 h post trauma for biochemical investigations.

**Tissue processing**

Sample preparation for the analysis was carried out as previously described. Briefly, animals were euthanized with Fatal Plus® (Vortech, Dearborn, MI), rapidly killed and the brain removed. An 8-mm punch was used to sample the ipsilateral (IP) site of cortical impact and the underlying hippocampus was isolated. The corresponding contralateral (CON) cortex and hippocampus were also sampled. At the time of dissection, none of the samples were compromised by the presence of surface blood products. These samples were immediately frozen in liquid nitrogen and stored at −80°C until used for analysis. Tissues were lysed using an ultrasonic cell disruptor (Microson Farmingdale, NY) on ice in 2.0 mL 0.1M, PBS (pH 7.4) containing 10 mM HEPES, 2.0 mM EDTA, 2.0 mM EGTA, 0.6 mM MgSO4, 4.6 mM KCl, and protease inhibitors cocktail (Millipore Inc.). Samples were centrifuged at 1000 g for 10 min/4°C to remove cell debris, and the collected supernatant was centrifuged at 15,000 g for 10 min/4°C. Supernatants were used for the analyses. Biochemical assays were completed in 96-well plates and analyzed with a SpectraMax® microplate reader ( Molecular Devices, Sunnyvale, CA). Total protein concentrations were determined using the Pierce BCA method (Sigma).

**Thiobarbituric acid reactive substance (TBARS)**

A marker of total oxidative damage was measured as previously described. Briefly, two sets of samples (0.2 mL) were simultaneously incubated at 37 ± 1°C and 0°C for 1 h. After 1 h of incubation, 0.2 mL of 10% trichloroacetic acid and 0.4 mL of 0.67% TBA were added to both sets of samples (i.e., 0°C and 37°C). The reaction mixture was vortexed and centrifuged at 3500 g for 15 min. The supernatant was then transferred to another tube and placed in a boiling water bath for 10 min. The samples were cooled to room temperature for 30 min, absorbance was recorded at 535 nm, and values were calculated by using a molar extinction coefficient of 1.56 × 10^5 M^-1 cm^-1.

**Pre- and post-synaptic proteins**

Synaptic marker proteins (synapsin-I, synaptophysin, drebrin, SAP-97, and PSD-95) were evaluated by Western blot as previously described. Briefly, samples were normalized for 50 μg protein in 25 μL of loading buffer and loaded with the appropriate marker on a gradient gel (4–20% Tris-HCl), followed by transfer to nitrocellulose membrane using a semi-dry transfer system (Bio-Rad) for 2 h at 15 volt. The membrane was blocked with 5% milk or bovine serum albumin (BSA) in Tris buffer/saline Tween-20 (TBST). Following the application of the primary antibody at the manufacturer’s recommended concentrations, membranes were incubated overnight at 4°C. Beta actin was also simultaneously probed as a loading control. The blots were then washed three times in TBST and incubated for 1 h with alkaline phosphatase conjugated secondary antibodies in a 1:8000 dilution. The blots were developed in Sigma Fast™ BCIP/NBT tablets (Sigma), dried, scanned with Adobe Photoshop, and quantified with Scion Image (PC version of Macintosh-compatible NIH Image). Percent changes in levels of synaptic proteins were determined by comparing the IP hemisphere to the CON hemisphere, thus using each animal as its own control.

**Statistical analysis**

Dose and time-dependent differences in oxidative stress marker TBARS and synaptic marker protein levels are reported as mean ± standard deviation. Differences between the group means were evaluated with a two-way analysis of variance (ANOVA) (Time by Dose) coupled with a Fisher’s PLSD post hoc test when warranted (StatView 5.0, SAS Institute). For significance, alpha was set at 0.05.
Results

Oxidative damage (TBARS): Cortex

Levels of TBARS were elevated after injury regardless of treatment. A two-way ANOVA (Time by Dose) revealed a significant main effect for Time [F(2, 62) = 4.552; p < 0.05] indicating that as the delay increased between trauma and initiation of therapy the levels of TBARS increased (Fig. 1A). Post hoc comparison revealed that levels were significantly lower at 15 min compared to both 2 h and 4 h (p < 0.05). There was no difference between 2 h and 4 h (p > 0.1). There was a significant main effect for Dose [F(3, 62) = 32.116; p < 0.0001], indicating that the drug was significantly better at reducing oxidative stress than vehicle alone. Post hoc testing revealed that although the 10 mg/kg group reduced oxidative stress to a greater degree than 1 mg/kg (p < 0.05), it was not significantly better than the 5 mg/kg treatment. There was no significant interaction between Time and Dose [F(6, 62) = 0.474; p > 0.1].

Oxidative damage (TBARS): Hippocampus

Levels of TBARS in the hippocampus were evaluated using a two-way ANOVA. This analysis revealed a significant main effect for Dose [F(3, 62) = 26.024; p < 0.0001], indicating that the drug significantly altered the levels of oxidative damage (Fig. 1B). Post hoc testing revealed that levels of TBARS were significantly higher in the vehicle-treated group compared to all doses of PYC-treated subjects (p < 0.0001). The analysis failed to reveal a significant main effect for Time [F(2, 62) = 0.956; p > 0.1] or any interaction [F(6, 62) = 0.380; p > 0.1]. Increasing the time between the trauma and initiation of PYC therapy did not appear to alter the level of TBARS, indicating that the reduction observed at 4 h with PYC was equivalent to that at 15 min.

Synaptic proteins: Cortex

Five different synaptic proteins were evaluated at 96 h following the trauma. As can be seen in Figure 2A, all five were affected by the PYC therapeutic intervention. Two different pre-synaptic proteins (synapsin-I; synaptophysin) were evaluated. A two-way ANOVA (Time by Dose) for synapsin-I revealed a significant main effect for both Time [F(2, 62) = 6.267; p < 0.005] and Dose [F(3, 62) = 30.616; p < 0.0001] (Fig. 2B). As for the timing of the initiation of therapy, post hoc evaluation revealed that the 15 min and 2 h times were significantly better than 4 h delay (p < 0.05), and 15 min and 2 h were not significantly different (p > 0.05). Post hoc evaluation of the
dose data showed that in all cases the PYC-treated animals were significantly different from the vehicle-treated animals, showing increased levels of synapsin-I ($p < 0.0001$). In addition, animals treated with either 5 mg/kg or 10 mg/kg were significantly better than the 1 mg/kg PYC group ($p < 0.0005$). The two higher doses were not significantly different. There was no significant interaction between Time and Dose [$F(6,62) = 0.695; p > 0.1$].

The synaptophysin data mimicked the synapsin-I results (Fig. 2C). A two-way ANOVA (Time by Dose) revealed significant main effects for both Time [$F(2,62) = 4.451; p < 0.05$] and Dose [$F(3,62) = 12.873; p < 0.0001$]. Therapy at 15 min post trauma was significantly better than therapy initiated at 4 h ($p < 0.005$). In all cases, the PYC-treated animals demonstrated significantly greater levels of synaptophysin compared to vehicle-treated controls ($p < 0.005$). The post hoc comparisons also revealed that the higher doses (5 mg/kg; 10 mg/kg) were significantly better ($p < 0.05; p < 0.001$) than the 1 mg/kg cohort. There was no significant interaction between Time and Dose [$F(6,62) = 0.483; p > 0.1$].

Three different important postsynaptic proteins (drebrin, PSD-95, SAP-97) were also evaluated. Possible changes in drebrin were evaluated with a two-way ANOVA (Time by Dose) and, while there was a significant main effect for Dose [$F(3,62) = 17.320; p < 0.0001$], there was no significant effect for Time [$F(2,62) = 2.836; p > 0.05$] indicating that delaying the therapy was not responsible for a significant portion of the variance (Fig. 2D). Post hoc testing did reveal that the PYC treatment significantly increased levels of drebrin compared to vehicle treated subjects ($p < 0.01$) and that the 5 mg and 10 mg/kg groups were significantly better than the 1 mg/kg PYC group ($p < 0.005$). There was no significant interaction between Time and Dose [$F(6,62) = 0.441; p > 0.1$].

Evaluation of the SAP-97 results showed a significant main effect for Time [$F(2,62) = 3.884$] and Dose [$F(3,62) = 29,782; p < 0.0001$] (Fig. 2E). Animals treated at 15 min post trauma demonstrated significantly higher levels of SAP-97 compared to the 4 h delay group ($p < 0.01$) but were not significantly different from the 2 h cohort ($p > 0.1$). As with the other synaptic proteins, treatment with any dose of PYC significantly elevated levels of SAP-97 ($p < 0.0005$). Both the 5 mg/kg and 10 g/kg dosing were significantly better in elevating levels of SAP-97 compared to the lower 1 mg/kg dose. There was no significant interaction between Time and Dose [$F(6,62) = 0.391; p > 0.1$].

Possible changes in PSD-95 were also evaluated with a two-way ANOVA (Time by Dose) and demonstrated a significant main effect for both Time [$F(2,62) = 5.518; p < 0.01$] and Dose [$F(3,62) = 21,763; p < 0.0001$] (Fig 2F). Post hoc testing revealed that the 15 min initiation of therapy was significantly better than the 4 h delay ($p < 0.005$) but not significantly different from 2 h ($p > 0.05$). The PYC treatment, regardless of dose, significantly increased PSD-95 levels compared to vehicle-treated cohorts ($p < 0.001$). The 5 mg/kg and 10 mg/kg groups were not significantly different from each other ($p > 0.1$) but were significantly better than the 1 mg/kg treated animals ($p < 0.0005$). There was no significant interaction between Time and Dose [$F(6,62) = 0.461; p > 0.1$].

**FIG. 2** Changes in the levels of synaptic proteins in the ipsilateral cortex following a cortical contusion injury at 96 h. Both pre (synapsin-I (B); synaptophysin (C)) and post (drebrin (D), SAP-97 (E), PSD-95 (F)) synaptic proteins were significantly decreased in vehicle-treated animals, while PYC treatment afforded significant protection. (A) Typical immunoblot showing densities of the bands used in analysis. Time indicates the delay following injury when treatment was initiated. Each bar represents the group mean ± SD. *$p < 0.001$ compared to vehicle; #$p < 0.05$ compared to the lower 1 mg/kg dose.
Synaptic proteins: Hippocampus

Hippocampal synaptic proteins were altered in a manner similar to the cortex following the cortical contusion (Fig. 3A). Western blot analysis revealed a decline in both pre- and post-synaptic proteins. A two-way ANOVA (Time by Dose) for synapsin-I revealed a significant main effect for Dose \[F(3,62) = 24.029; p < 0.001\] but not for Time \[F(2,62) = 1.590; p > 0.1\] (Fig. 3B). Post hoc testing revealed that PYC, regardless of dose, significantly spared this synaptic marker compared to the vehicle-treated animals \(p < 0.0005\). The two higher doses were significantly better at protecting synapsin-I compared to the 1 mg/kg dose \(p < 0.005\) but were not different from each other \(p > 0.1\). There was no significant interaction between Time and Dose \[F(6,62) = 0.575; p > 0.1\].

Analysis of the synaptophysin data revealed a significant main effect for both Time \[F(2,62) = 4.386; p < 0.05\] and Dose \[F(3,62) = 13.456; p < 0.0001\] (Fig. 3C). Therapy at 15 min was significantly better at protecting this synaptic protein compared to a delay of 4 h \(p < 0.005\), but was not different from the 2 h delay \(p > 0.1\). The two higher doses of PYC showed significantly higher levels of synaptophysin compared to vehicle \(p < 0.0001\) and the lower PYC dose \(p < 0.001\), but were not different from each other \(p > 0.1\). There was no significant interaction between Time and Dose \[F(6,62) = 0.575; p > 0.1\].

Changes in the post synaptic protein, drebrin, showed a Time \[F(2,62) = 3.758; p < 0.05\] and Dose \[F(3,62) = 22.334; p < 0.0001\] change in levels with PYC therapy (Fig. 3D). As with the pre synaptic proteins, delaying therapy for 4 h significantly affected levels compared to 15 min \(p < 0.01\). All groups treated with PYC were significantly better at protecting drebrin levels. The two higher doses provided the greatest protection \(p < 0.0001\) and were also significantly better compared to the 1 mg/kg group \(p < 0.0001\). There was no significant interaction between Time and Dose \[F(6,62) = 0.924; p > 0.1\].

A two-way analysis of the SAP-97 data showed a robust dose effect \[F(3,62) = 44.177; p < 0.0001\], but no main effect for Time \[F(2,62) = 3.090; p > 0.05\] (Fig. 3E). Post hoc testing revealed that PYC, regardless of dose, was significantly better at protecting the SAP-97 protein \(p < 0.0001\) compared to vehicle. In addition, the two higher doses of PYC (5 mg/kg; 10 mg/kg) showed significantly greater levels \(p < 0.005\) than the 1 mg/kg group. There was no significant interaction between Time and Dose \[F(6,62) = 0.924; p > 0.1\].

Analysis of the PSD-95 results revealed changes similar to the other post synaptic proteins (Fig. 3F). There was a significant main effect for Dose \[F(3,62) = 11.993; p < 0.0001\], but no significant main effect for Time \[F(2,62) = 2.986; p > 0.05\]. PYC treatment, regardless of dose showed significantly greater protection of PSD-95 compared to the vehicle treated groups \(p < 0.005\). The 10 mg/kg group showed the greatest sparing and was significantly greater than the 1 mg/kg cohort \(p < 0.05\) but not the 5 mg/kg group \(p > 0.1\). There was no significant interaction between Time and Dose \[F(6,62) = 0.560; p > 0.1\].
Discussion

This is the first study evaluating possible neuroprotective aspects of PYC therapy in a clinically relevant fashion in a well-established animal model of TBI. Animals treated i.v. post injury with PYC showed significant neuroprotective effects. PYC treatment reduced oxidative stress and spared both pre- and post-synaptic proteins in both the cortex and hippocampus. The levels of neuroprotection were affected by the different doses of PYC administered. In addition, we showed that the therapeutic window can be extended up to at least 4 h post trauma.

Oxidative stress is a key component of the secondary injury cascades following TBI. The brain is highly sensitive to oxidative damage because of its high content of polyunsaturated fatty acids, which are vulnerable to free radical attacks and lipid peroxidation. Significant increases can be observed as early as 30 min post trauma. Levels of oxidative stress peak around 24 to 48 h after injury. We previously reported that when PYC (100 mg/kg) was administered in multiple i.p. injections, there was a significant reduction in oxidative stress following a moderate/severe TBI. The present experiments used a more clinically relevant paradigm by treating animals with a single i.v. injection of PYC. Compared to the i.p. administration, animals receiving the single i.v. injection were afforded greater reduction in oxidative stress. However, even with early i.v. treatment (i.e., 15 min), the levels of oxidative stress were elevated compared with the uninjured hemisphere. These results support the idea that secondary injury cascades occur very rapidly following TBI but can be manipulated with therapeutic intervention including bioflavonoids.

The neuroprotective effects of PYC are not confined to a single cell type or region of the brain. As in our previous study, PYC showed significant effects in both the injured cortex and hippocampus. Both regions showed a dose-dependent effect in regards to both the levels of oxidative stress and the sparing of synaptic proteins. Even the lowest dose evaluated (1 mg/kg) showed significant protection when compared to vehicle-treated animals, while the highest levels (10 mg/kg) afforded the greatest neuroprotection. Differences between 5 mg/kg and 10 mg/kg were only discernible in relatively few comparisons. These neuroprotective effects occurred in both regions of interest. The sparing of synaptic proteins in both brain regions is very important because it indicates a possible sparing of synaptic contacts that are known to be disrupted following TBI.

For a therapeutic compound to be considered clinically relevant, it must provide a significant effect when the therapy onset is delayed for an extended time post trauma. To explore the therapeutic window, onset of PYC treatment was initiated at different times post trauma. There was a significant time effect in the injured cortex. Animals treated with PYC at 15 min demonstrated significantly lower levels of oxidative stress compared to a 2 or 4 h delay following injury. There was no significant difference observed between 2 and 4 h treatment of PYC. The hippocampus failed to show a significant time effect, indicating that the significant reduction in oxidative stress was just as effective at 4 h as it was when initiated at 15 min. One possible explanation might be because the level of oxidative stress was substantially lower in the hippocampus compared with the ipsilateral cortex. This might indicate that PYC treatment may show its maximum benefit under conditions of mild TBI.

There were limited effects of therapy delay in both the cortex and hippocampus in regards to the protection of synaptic proteins. In the cortex, there were significant differences between 15 min and 4 h for SAP-97, synapsin-I, synaptophysin, and PSD-95. In the hippocampus, these two times differed for synaptophysin and drebrin. However, these differences were not very robust. There were no differences between 15 min versus 2 h delay or between the 2 h and 4 h delay. In all cases, PYC treatment significantly spared synaptic proteins in both regions, regardless of the dose or time of treatment onset. This was an expected outcome considering the decline in synaptic proteins is known to be delayed following trauma and i.p. treatment of PYC previously demonstrated strong protective effects. Maximum changes in the synaptic protein levels have previously been reported at 96 h following an identical injury with no significant changes occurring within the first 6 to 12 hours. These results support the idea that i.v. injection of PYC has a reasonable therapeutic window. It has yet to be determined whether neuroprotective timing can be extended even further.

Bioflavonoids are unique compounds, present ubiquitously in nature and found in high concentrations in many fruits, vegetables, tea, cocoa, and wine. Previous studies have shown that rodents can tolerate extremely high doses of bioflavonoids without any significant detrimental effects. A human clinical study reported that elderly individuals tolerated 150 mg/day of PYC for 3 months without any significant side effects. PYC has very low acute and chronic toxicity with mild unwanted effects occurring in a small percentage of human subjects. The beneficial effects of PYC indicate it can cross a compromised blood-brain barrier, which is breached soon after injury.

Various studies indicate that bioflavonoids may have neuroprotective effects in TBI. Bioflavonoids have the ability not only to reduce inflammation, brain edema, and neuronal death, but can improve both motor and cognitive function in rodents after TBI. PYC has the unique characteristic of providing a multifaceted approach of neuroprotection, demonstrated by the fact it reduced inflammation, decreased oxidative damage, and spared synaptic proteins in the brain following TBI. The neuroprotective effects of PYC are likely more than just free radical quenching. Bioflavonoids can interact with various cell signaling cascades. Among those cascades, some of the enzymes and related mechanisms have been well investigated in neurotrauma. The interaction of the bioflavonoids with these cascades can inhibit apoptotic processes and improve cell survival.

In conclusion, this study demonstrates the substantial neuroprotective effects of PYC following moderate to severe TBI in rats by reducing oxidative stress and sparing synaptic proteins. The results show a relatively long therapeutic window (up to 4 h) for PYC treatment following neurotrauma, with the same protective effects in both the cortex and the hippocampus. For i.v. treatment, 5–10 mg/kg PYC is a sufficient dose to use for protection without toxicity. It has yet to be determined what specific mechanisms may be responsible for the neuroprotective effects of PYC. It will be important to determine if specific cell signaling cascades or molecular changes in the transcriptional factors may be influenced. Additional studies are needed to determine whether these same neuroprotective effects of PYC will be observed in other TBI models.

Acknowledgments

This work was supported by National Institute of Health Grant R21NS66117 and Kentucky Spinal Cord Brain Injury Trust 12-16A. Pycnogenol® was a very generous gift from Horphag Research Inc., Hoboken, NJ.
Author Disclosure Statement
No competing financial interests exist.

References


Address correspondence to:
Stephen W. Scheff, PhD
101 Sanders-Brown Center on Aging
University of Kentucky
Lexington, KY 40536-0230

E-mail: sscheff@email.uky.edu

Abbreviations Used
ATP = adenosine triphosphate
BSA = bovine serum albumin
CON = contralateral
EDTA = ethylenediaminetetraacetic acid
EGTA = ethylene glycol tetraacetic acid
HEPES = 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
IP = ipsilateral
PSD-95 = post synaptic density 95
PYC = pycnogenol
SAP-97 = synapse associated protein 97
TBARS = thiobarbituric acid reactive substance
TBI = traumatic brain injury
TBST = Tris buffer/saline-Tween-20

1549
This article has been cited by:
